Go to deals
Healthcare

Groupe Serenis has raised capital from BNP Paribas Dev., GSO Capital and Multicroissance

Groupe Serenis has raised US$8 million in equity from BNP Paribas Developpement, Credit Agricole GSO Capital and Multicroissance Banque Populaire Occitane.

Groupe Serenis operates nursing homes, residential units for disabled elderly people and geriatric clinics in the southwest of France, focusing on the high end of the dependency spectrum. A family group incorporated in 1956, Serenis is now taking a new step of development through a partnership with Kaufman&Broad, a French real estate developer, to create a network of nursing homes.

Oaklins' team in France assisted the shareholders of Serenis in this transaction to find private equity investors ready to assist and support them in this new ambitious step in the group's development.

Talk to the deal team

Raphaël Petit

Managing Partner
Toulouse, France
Oaklins France

Xavier Auvergnat

Partner
Toulouse, France
Oaklins France

Related deals

Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Healthcare

Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval

Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.

Learn more
Rare Patient Voice has been acquired by Konovo
Healthcare | TMT

Rare Patient Voice has been acquired by Konovo

Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.

Learn more
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
Healthcare

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Learn more